Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
JM Llovet, R Pinyol, RK Kelley, A El-Khoueiry… - Nature cancer, 2022 - nature.com
Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …
The poor outcome associated with HCC is dramatically changing due to the advent of …
Advances in molecular classification and precision oncology in hepatocellular carcinoma
S Rebouissou, JC Nault - Journal of hepatology, 2020 - Elsevier
Hepatocellular carcinoma (HCC) arises from hepatocytes through the sequential
accumulation of multiple genomic and epigenomic alterations resulting from Darwinian …
accumulation of multiple genomic and epigenomic alterations resulting from Darwinian …
Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020)
PK Haber, M Puigvehí, F Castet, V Lourdusamy… - Gastroenterology, 2021 - Elsevier
Background & Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related
mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous …
mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous …
Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
EASL clinical practice guidelines: management of hepatocellular carcinoma
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
Molecular and histological correlations in liver cancer
J Calderaro, M Ziol, V Paradis, J Zucman-Rossi - Journal of hepatology, 2019 - Elsevier
Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer, both at the molecular
and histological level. High-throughput sequencing and gene expression profiling have …
and histological level. High-throughput sequencing and gene expression profiling have …
Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma
Background: Potential prognostic biomarker candidates for hepatocellular carcinoma (HCC)
are abundant, but their generalizability is unexplored. We cross-validated markers of overall …
are abundant, but their generalizability is unexplored. We cross-validated markers of overall …
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled …
L Rimassa, E Assenat, M Peck-Radosavljevic… - The Lancet …, 2018 - thelancet.com
Summary Background Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved
overall survival and progression-free survival compared with placebo in a randomised …
overall survival and progression-free survival compared with placebo in a randomised …
Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide.
Around half of patients with HCC will receive systemic therapies during their life span. The …
Around half of patients with HCC will receive systemic therapies during their life span. The …
Genomic medicine and implications for hepatocellular carcinoma prevention and therapy
R Dhanasekaran, JC Nault, LR Roberts… - Gastroenterology, 2019 - Elsevier
The pathogenesis of hepatocellular carcinoma (HCC) is poorly understood, but recent
advances in genomics have increased our understanding of the mechanisms by which …
advances in genomics have increased our understanding of the mechanisms by which …